Quest Diagnostics said New York State's Clinical Laboratory Evaluation Program approved its Haystack MRD test for detecting residual or recurring disease in patients with solid tumors. The approval expands regulatory clearance for the company's oncology testing offering and supports its precision diagnostics platform. The news is positive for Quest, though the near-term market impact is likely limited.
Quest Diagnostics said New York State's Clinical Laboratory Evaluation Program approved its Haystack MRD test for detecting residual or recurring disease in patients with solid tumors. The approval expands regulatory clearance for the company's oncology testing offering and supports its precision diagnostics platform. The news is positive for Quest, though the near-term market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
